Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy

Autor: Evandro de Azambuja, Sherene Loi, Martine Piccart, Denis Larsimont, Angelo Di Leo, Marianne Paesmans, Ivana Bozovic-Spasojevic, Lieveke Ameye, Stella Dolci
Rok vydání: 2013
Předmět:
Oncology
Carcinoma
Lobular -- drug therapy -- metabolism -- pathology
medicine.medical_treatment
Antibiotics
Antineoplastic -- therapeutic use
Expression
Carcinoma
Ductal
Breast -- drug therapy -- metabolism -- pathology
Breast cancer
Antineoplastic Combined Chemotherapy Protocols
Tumor Markers
Biological -- metabolism
TP53
Antibiotics
Antineoplastic
Breast Neoplasms -- drug therapy -- metabolism -- pathology
Carcinoma
Ductal
Breast
General Medicine
Middle Aged
Prognosis
Primary tumor
medicine.anatomical_structure
Treatment Outcome
Proto-Oncogene Proteins c-bcl-2
Cisplatin -- therapeutic use
Chemotherapy
Adjuvant
Female
Fluorouracil
Adjuvant
Adult
medicine.medical_specialty
BCL2
Randomization
Axillary lymph nodes
Anthracycline
Concordance
Breast Neoplasms
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Disease-Free Survival
Internal medicine
Epirubicin -- therapeutic use
medicine
Methotrexate -- therapeutic use
Tumor Suppressor Protein p53 -- metabolism
Biomarkers
Tumor
Humans
Chirurgie
neoplasms
Aged
Epirubicin
Retrospective Studies
Gynecology
Chemotherapy
Proto-Oncogene Proteins c-bcl-2 -- metabolism
business.industry
Fluorouracil -- therapeutic use
medicine.disease
Carcinoma
Lobular
Methotrexate
Axilla
Surgery
Lymph Nodes
Cisplatin
Tumor Suppressor Protein p53
business
Lymph Nodes -- metabolism -- pathology
Biomarkers
Zdroj: Breast, 23 (4
ISSN: 1532-3080
Popis: Given recent data on genetic heterogeneity within and individual's tumor, we investigated if there were differences in the prognostic and predictive abilities of BCL2 and TP53 protein expression in primary breast cancer (TU) and corresponding axillary lymph-nodes (LN). We used patient samples from the adjuvant Belgian three-arm study which randomized between anthracycline containing regimens and traditional CMF. The endpoints analyzed were overall survival (OS), event-free survival (EFS) and interactions between chemotherapy regimens.At a median follow-up of 15.6 years, BCL2 and TP53 (in both TU and LN) were significantly associated with OS but only in the first 5 years. Likewise, BCL2 and TP53 (in both TU and LN) were associated with EFS in the first 2 years after randomization, with no association after 2 years. BCL2 and TP53 remained statistically significant after adjustment for the standard clinical-pathological characteristics in regard to OS and EFS in the respective first years after randomization, (p value < 0.001 for both markers).Furthermore, an interaction was found between high BCL2 expression in the TU (but not in LN) and benefit to CMF over anthracycline-based chemotherapy (interaction p value EFS: 0.042; OS = 0.01). No interaction was found for TP53 expression neither in TU nor in LN.We conclude that BCL2 and TP53 were predictive biomarkers for better and worse survival respectively, but only in the first two to five years after diagnosis. BCL2 expression in the TU but not in the LN was predictive of increased benefit to CMF vs anthracycline-based chemotherapy. © 2014 Elsevier Ltd.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: